Decinjet Drug Interactions

No formal clinical drug interaction studies with Decitabine have been conducted. There is the potential for a drug-drug interaction with other agents which are also activated by sequential phosphorylation (via intracellular phosphokinase activities) and/or metabolised by enzymes implicated in the inactivation of Decitabine (e.g., cytidine deaminase). Therefore, caution should be exercised if these active substances are combined with Decitabine.
Impact of co-administered medicinal products on Decitabine: Cytochrome (CYP) 450-mediated metabolic interactions are not anticipated as Decitabine metabolism is not mediated by this system but by oxidative deamination.
Impact of Decitabine on co-administered medicinal products: Given its low in vitro plasma protein binding (<1%), Decitabine is unlikely to displace co-administered medicinal products from their plasma protein binding. Decitabine has been shown to be a weak inhibitor of P-gp mediated transport in vitro and is therefore, also not expected to affect P-gp mediated transport of co-administered medicinal products (see Pharmacology: Pharmacokinetics under Actions).